R&D

Defining, building, and implementing the next wave of biopha...

In a new podcast, pharmaphorum speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma.

News

AstraZeneca reveals $570m investment in Canada

AstraZeneca has announced another major investment in Canada, tapping into the country's emergence as a "global hub" for clinical trials.

Market Access

Graphic of an upward trajectory arrow with woman and telescope atop

The biopharma outlook for 2025: Opportunities and challenges

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap

R&D

Graphic of man with briefcase using large magnifying glass to search for something

Focusing too many R&D resources on one drug: The hidden cost...

Drug development is a high-stakes, high-cost endeavour.

News

GSK builds neuro, cancer pipeline with trio of deals

GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.

News

Abingworth 'will launch $1.5bn fund for co-developed drugs'

Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.

Defining, building, and implementing the next wave of biopha...

AstraZeneca reveals $570m investment in Canada

The biopharma outlook for 2025: Opportunities and challenges

Focusing too many R&D resources on one drug: The hidden cost...

GSK builds neuro, cancer pipeline with trio of deals

Abingworth 'will launch $1.5bn fund for co-developed drugs'

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

R&D

Editor's Picks